Inhibitor Therapeutics, Inc. (INTI)
Stock Price:
$0.0550 USD
-0.0030 (-5.17%)
Updated Oct 19, 2020 11:40 AM EDT - Market closed
Key Info
| Market Cap |
20.55M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-2.01M |
| Shares Out |
373.64M |
| EPS (ttm) |
-0.01 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$0.0550 |
| Previous Close |
$0.0580 |
| Change ($) |
-0.0030 |
| Change (%) |
-5.17% |
| Day's Open |
0.0550 |
| Day's Range |
0.0550 - 0.0550 |
| Day's Volume |
14,850 |
| 52-Week Range |
0.0064 - 0.114 |
More Stats
| Market Cap |
20.55M |
| Enterprise Value |
20.45M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
373.64M |
| Float |
77.90M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.01 |
| FCF / Share |
-0.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
19,880 |
| Short Ratio |
0.07 |
| Short % of Float |
0.03% |
| Beta |
-0.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
76.91 |
| Revenue |
n/a |
| Operating Income |
-2.02M |
| Net Income |
-2.01M |
| Free Cash Flow |
-1.83M |
| Net Cash |
95,717 |
| Net Cash / Share |
0.00 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-107.61% |
| ROE |
n/a |
| ROIC |
685.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
3.50
Current: $0.0550
High
3.50
Target: 3.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -2.75 | -4.56 | -5.12 | -7.02 | -3.95 | -3.94 | -2.00 | -0.56 | -0.98 | -1.03 |
| Net Income | -2.73 | -4.55 | -5.10 | -7.00 | -3.95 | -3.98 | -1.84 | 0.19 | -0.23 | -1.00 |
| Shares Outstanding | 370 | 370 | 367 | 289 | 233 | 95.88 | 17.94 | 13.65 | 12.66 | - |
| Earnings Per Share | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.04 | -0.10 | 0.01 | -0.02 | -0.10 |
| Operating Cash Flow | -2.71 | -3.71 | -2.91 | -3.76 | -2.26 | -1.30 | -1.22 | -0.46 | 0.07 | -0.17 |
| Capital Expenditures | - | - | - | - | - | - | - | - | 1.37 | - |
| Free Cash Flow | -2.71 | -3.71 | -2.91 | -3.76 | -2.26 | -1.30 | -1.22 | -0.46 | 1.44 | -0.17 |
| Cash & Equivalents | 0.80 | 1.11 | 0.34 | 6.89 | 0.60 | 0.37 | 0.00 | 0.86 | 1.32 | 0.10 |
| Total Debt | - | - | - | - | - | - | 0.07 | - | 0.67 | 3.73 |
| Net Cash / Debt | 0.80 | 1.11 | 0.34 | 6.89 | 0.60 | 0.37 | -0.07 | 0.86 | 0.66 | -3.63 |
| Assets | 0.90 | 1.23 | 0.77 | 7.34 | 0.89 | 0.46 | 0.01 | 0.94 | 1.40 | 6.15 |
| Liabilities | 3.43 | 1.20 | 0.60 | 0.31 | 0.46 | 0.40 | 0.78 | 1.07 | 1.77 | 5.75 |
| Book Value | -2.53 | 0.03 | 0.17 | 7.03 | 0.42 | 0.06 | -0.77 | -0.13 | -0.37 | 0.40 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Inhibitor Therapeutics, Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Nicholas Jon Virca |
Stock Information
| Ticker Symbol |
INTI |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: INTI |
Description
Inhibitor Therapeutics operates as a pharmaceutical development company that discovers, develops, and plans to commercialize therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders in the United States. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity, and cell proliferation. It focuses on developing its lead product, SUBA-Itraconazole, a patented oral formulation for prostate and lung cancer. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics Inc. in August 2019. Inhibitor Therapeutics Inc. was founded in 1992 and is based in Tampa, Florida.